Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5184329 | 0.81 | TYMP (0.42) | CASP3ASAH1FAAH | |
| SCHEMBL17844195 | 0.74 | ASPH (0.41) | ASAH1 | |
| SCHEMBL5184337 | 0.73 | MAOA (0.42) | ASAH1 | |
| SCHEMBL17844110 | 0.73 | MAOA (0.40) | ASAH1 | |
| SCHEMBL2001616 | 0.71 | CA12 (0.40) | ASAH1CACNA1GCACNA1HMAPT | |
| SCHEMBL17844245 | 0.71 | CYP1A2 (0.42) | CASP7 | |
| SCHEMBL17844216 | 0.70 | EPHX1 (0.40) | ASAH1GSK3B | |
| SCHEMBL5186011 | 0.68 | ALDH1A1 (0.48) | MAPTTP53FAAH | |
| SCHEMBL17844169 | 0.66 | SCN9A (0.36) | — | |
| SCHEMBL17844161 | 0.66 | FAAH (0.44) | MAPTTP53CASP7FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | claimed |
| WO-2016100619-A2 | TREATMENT AND DIAGNOSIS OF CANCER | RGENIX, INC. (US) | 2016-06-23 | — | — | WO | disclosed |